CDN1163, an allosteric pan‐SERCA activator in vitro and in vivo,[36] has been demonstrated to be potentially therapeutic in various animal models of oxidative stress‐related diseases, such as 6‐Hydroxydopamine hydrochloride (6‐OHDA)‐lesioned rats as a model of Parkinson's disease and superoxide dismutase 1 (SOD1)‐deficient mice.[15, 37] Both the reduced SR calcium storage and inhibited SERCA activity in Huwe1 knockout cells were improved by CDN1163 treatment (Figure 5A,B). This evidence concerns the gene SOD1 and Parkinson disease.